Introduction & Objective: Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality for heart failure. We demonstrated that 4-weeks-treatment with SGLT-2i leads to a 30% increase in coronary flow reserve (CFR) in T2D people with stable coronary artery disease (CAD) (DAPAHEART trial). The aim of this study is to evaluate the long-term effects of treatment with dapagliflozin on CFR in patients with T2D.

Methods: T2D patients with CAD already enrolled for a single-center, 4 weeks, prospective, randomized (1:1 dapagliflozin 10 mg or placebo), double-blind, controlled study have been followed up for 4 years. At the end of the trial all the patients in placebo group started therapy with dapagliflozin. After 4 years of treatment the CFR has been evaluated using 13N-ammonia PET-CT.

Results: During the follow-up, the antidiabetic treatment remained stable. The 2 groups were metabolically well balanced.In DAPA group (n=5), the increase of 30% in CFR was sustained over 4 years (p=ns). A comparison between pre and post-4-years follow-up in DAPA group showed a 35% increase in CFR (p=0.09). The placebo group (n=4), after 4 years of dapagliflozin treatment, exhibited a 28.6% increase in CFR (p=0.07). Overall, a 25% increase in CFR was observed across all patients after 4 years (p=0.008, n=9), along with a reduction in myocardial resting blood flow (p=0.002, n=9) as observed in the DAPAHEART trial.

Conclusions: This 4-years follow up trial demonstrates that the 30% increase of CFR obtained after 4 weeks treatment is maintained after 4 years, confirming the previous published results in a new population. This improvement in CFR may have important implications on the management and prognosis of patients with T2D and CAD.

Keywords: Coronary Flow Reserve, SGLT2i, Dapagliflozin, Type 2 Diabetes, Coronary Artery Disease, Long-Term.

Disclosure

C. Morciano: None. F. Cinti: None. G. Sorice: None. L. Leccisotti: None. S. Gugliandolo: None. U. Capece: None. L. Cappannoli: None. D. D'amario: None. T. Mezza: None. G. Di Giuseppe: None. G. Ciccarelli: None. L. Soldovieri: None. A. Giaccari: None.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.